Abstract: The present invention refers to a process for producing cellulose of market eucalyptus fibers having distinct features through the use of at least one enzymatic treatment with hydrolytic enzymes, such as for example, xylanases, cellulases or mixtures thereof, in association to at least one acidic treatment step. These treatments may be applied into different steps of the fibers process producing, wherein all of them happen before drying.

Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture is compatible with biologic function.

Abstract: Provided herein are methods of increasing the efficiency of biomass saccharification. In particular, the methods include ways of avoiding feedback inhibition of enzymatic reactions during the production of useful products. The methods also include saccharifying recalcitrance-reduced lignocellulosic biomass and adding an isomerization agent to the saccharified biomass. The saccharified biomass can be further converted into products by a microorganism.

Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.

Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

Abstract: The invention relates to a process for production of biogas from a biodegradable substrate under anaerobic conditions, comprising the steps of introducing the substrate into a reaction space, the addition of a lime-based material having a particle diameter (d97) of less than 90 ?m and/or (d50) of less than 10 ?m to the substrate, and the biodegradation of the substrate to form biogas.

Abstract: Formulations and methods are disclosed for the harvesting and subsequent passaging of human pluripotent stem cells without the use of enzymes and/or scraping to dislodge cells from cell culture vessels. The formulations and methods permit the harvesting of cells as large clusters from the surface of various cell culture vessels including multilayer cell culture vessels. Further, the formulations and methods provide high yields of harvested cells for subsequent passaging and high post-harvest cell viability. Pluripotent stem cells passaged with the formulations according to the methods remain undifferentiated and express typical stem cell markers, while, at the same time, they retain the differentiation capability and are able to differentiate into the cells in all three germ layers and generate teratomas, even after numerous rounds of harvesting and passaging. These hPSCs also maintain normal karyotype after passaged with the formulations for extended period of time.

Abstract: A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process.

Abstract: A composition remediation of soil and groundwater containing halogenated compounds. The remediation composition includes an elemental iron-based composition, which may include activated carbon capable of absorbing the halogenated compounds with numerous pores impregnated with elemental iron. The remediation composition further includes a first bioremediation material including a blend of one-to-many organisms capable of degrading the halogenated compounds. The remediation composition includes an organic compound or polymeric substance and a second bioremediation material including a blend of one-to-many organisms capable of degrading the organic compound or polymeric substance over time (e.g., 20 to 365 or more days to provide a time release substrate-creating material or platform) into smaller molecules or compounds used by the organisms in the first bioremediation material while degrading the halogenated compounds.

Abstract: The invention relates to progenitor cells of mesodermal lineage and their use in therapy.

Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method may include a method of treating an infection. The method may comprise administering a microbiota restoration therapy composition to a patient with an infection. The microbiota restoration therapy composition may comprise a mixture of an effective amount of fecal microbiota and an effective amount of polyethylene glycol.

Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method may include a method of treating an infection. The method may comprise administering a microbiota restoration therapy composition to a patient with an infection. The microbiota restoration therapy composition may comprise a mixture of an effective amount of fecal microbiota and an effective amount of polyethylene glycol.

Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

Abstract: The present invention relates to the treatment and/or prophylaxis of storage diseases of harvested material. This object is achieved by the use of the bacterium of Pseudomonas sp. Proradix (DSMZ 13134). This object is further achieved by a method comprising provision of harvested material, contacting said harvested material with a solution containing the bacterium of Pseudomonas sp. Proradix (DSMZ 13134), and storing the harvested material outside of the ground soil.

Abstract: The present disclosure describes a method of processing a biological sample. The method includes contacting the sample with a pH indicator that changes color in response to changes in pH. The presence of a pH indicator such as cresol red provides the benefit of improved visualization of the sample, verification that the sample is properly frozen and thawed, and increased precision in pH adjustments during the assay, among other benefits.

Abstract: The invention concerns methods of treating stored blood and blood products maximizing shelf life and/or minimizing transfusion related complications such as non¬ hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood and blood products milieu through use of a sorbent.

Abstract: The present invention includes compositions and methods for eliminating or reducing microbial contamination in lymph nodes that enter the food supply from livestock comprising: identifying an animal in need of eliminating or reducing microbial contamination in non-gut associated lymph nodes that enter the food supply, and providing the animal with an effective amount of a lactic acid bacteria or probiotic bacterial sufficient to reduce or eliminate the microbial contamination in non-gut associated lymph nodes.

Abstract: The present invention relates to processes of producing a fermentation product from readily fermentable sugar-material in a fermentation vat comprising a fermentation medium, comprising: feeding the readily fermentable sugar-material into the fermentation vat comprising a slurry of fermenting organism; fermenting the readily fermentable sugar material into a desired fermentation product, wherein protease is added during or after feeding of the readily fermentable sugar-material into fermentation vat or during fermentation of the readily fermentable sugar-material into the desired fermentation product. The invention also related to the use of protease for reducing foaming in the fermentation yells generating by the fermenting organism during fermentation of the readily fermentable sugar-material.

Abstract: A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition. The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.